# A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

> **NCT05943795** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 589 (actual)

## Conditions studied

- Non-small Cell Lung Adenocarcinoma
- Squamous Cell Carcinoma of Lung

## Interventions

- **DRUG:** SI-B001
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05943795
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 589 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943795, "A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05943795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*